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A B S T R A C T
Drug penetration into solid tumours remains a major challenge in the effective treatment of cancer. Microbubble
(MB) mediated sonoporation offers a potential solution to this by enhancing the uptake of drugs into cells.
Additionally, in using an ultrasound (US) trigger, drug delivery can be localised to the tumour, thus reducing the
off-site toxicity associated with systemic delivery. The majority of in vitro studies involving the observation of
MB-enhanced drug efficacy have been conducted on 2D monolayer cell cultures, which are known to be poor
models for in vivo tumours. 3D spheroid cultures allow for the production of multicellular cultures complete with
extracellular matrix (ECM) components. These cultures effectively recreate many of the physiological features of
the tumour microenvironment and have been shown to be far superior to previous 2D monolayer models.
However, spheroids are typically handled in well-plates in which the fluid environment is static, limiting the
physiological relevance of the model. The combination of 3D cultures and microfluidics would allow for the
production of a dynamic system in which spheroids are subjected to in vivo like fluid flow and shear stresses. This
study presents a microfluidic device containing an array of spheroid traps, into which multiple pre-grown col-
orectal cancer (CRC) spheroids were loaded. Reservoirs interfaced with the chip use hydrostatic pressure to
passively drive flow through the system and subject spheroids to capillary like flow velocities. The use of re-
servoirs also enabled multiple chips to be run in parallel, allowing for the screening of multiple therapeutic
treatments (n = 690 total spheroids analysed). This microfluidic platform was used to investigate MB enhanced
drug delivery and showed that co-delivery of 3 μM doxorubicin (DOX) + MB + US reduced spheroid viability to
48 ± 2%, compared to 75 ± 5% observed with 3 μM DOX alone. Delivery of drug loaded MBs (DLMBs), in
which DOX-loaded liposomes (DOX-LS) were conjugated to MBs, reduced spheroid viability to 62 ± 3%, a
decrease compared to the 75 ± 3% viability observed with DOX-LS in the absence of MBs + US.
1. Introduction
Typical in vitro 2D monolayer cell cultures used to test many po-
tential anticancer therapeutics fail to effectively recreate many phy-
siological features of in vivo tumours [1]. While they present valuable
simplistic models to investigate fundamental biology, their use as drug
assessment platforms are limited. Drugs that appear to have high effi-
cacy against monolayer models, often don't translate these outcomes to
more complex in vivo systems. Monolayer cultures lack cell-cell con-
nections, multicellular compositions and extracellular matrix (ECM)
components, resulting in their failure to produce results observed in the
clinic [1–3]. 3D spheroid culture models have been developed to help
overcome many of these shortcomings, using aggregates of multiple cell
types to form 3D tumour cultures. Moreover, the structure of solid tu-
mours is more faithfully recreated in spheroids, which consist of a ne-
crotic core with a surrounding hypoxic region composed of quiescent
cells bounded by a rapidly proliferating outer layer [4,5]. Indeed, it has
been shown that the 3D tumour co-cultures produce a model which
more effectively predicts the clinical effects of anticancer drugs, com-
pared to 2D model counterparts [2,6–8].
The inclusion of fibroblasts into 3D spheroid cultures has proved to
be a crucial component in creating a physiological tumour model.
Fibroblasts cultured alongside tumour cells differentiate to become
cancer-associated fibroblasts (CAFs), also known as myofibroblasts
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[9–11]. Characterised by the expression of alpha smooth muscle actin
(α-SMA), CAFs secrete a myriad of growth factors, chemokines and
ECM proteins that promote tumour growth, metastasis and drug re-
sistance [11–16]. Responsible for many of the physical characteristics
tumours display, CAFs increase the stiffness and density of the tumour
ECM, limiting the penetration and effectiveness of many chemother-
apeutics. Several studies have investigated the link between the pre-
sence of CAFs and the progression of colorectal cancers (CRCs), finding
that an abundance of CAFs is associated with more aggressive tumours
and a lower overall rate of disease free survival [12,17–20]. This em-
phasises the need for the incorporation of multiple cell types in tumour
cultures, if a physiologically relevant model is to be achieved to im-
prove the accuracy in predicting drug efficacy in pre-clinical testing.
The rise of spheroid cultures for drug toxicity assays has highlighted
one of the main issues with current cancer treatment methods – the lack
of drug penetration into solid tumours. The physical barrier of ECM
proteins produced by CAFs, along with inherent drug resistance dis-
played by quiescent cells, results in many anticancer drugs failing to
have a significant effect on tumour progression [11,21–23]. MB-medi-
ated sonoporation, induced by the application of an ultrasound (US)
wave, offers a promising solution to this issue and has been studied
extensively as a method by which drug uptake in cells can be increased
[24–31]. US alone has been shown to increase membrane permeability
through the formation of membrane pores [32,33]. This effect is in-
creased in the presence of MBs, which undergo oscillations that can
result in jet formation and localised shear flow, disrupting nearby cell
membranes [34,35]. This has been shown to effectively deliver target
molecules to cells, specifically enhancing drug uptake due to the
openings created in cell membranes. The majority of these studies,
however, have been conducted on 2D monolayers of cells, meaning MB
effectiveness in 3D cultures is still relatively undocumented. Recent
studies have begun testing MB therapies on 3D static spheroid cultures,
observing the effects of delivering drug-loaded liposomes conjugated to
MBs. Roovers et al. have shown that MB-induced sonoporation results
in the ‘sonoprinting’ of liposomes (LSs) from DOX-LS-loaded MBs onto
the spheroid surface. This resulted in increased liposome cytotoxicity
compared to LSs alone and was hypothesised to allow for lower doses of
DOX to be administered in the clinic with the same efficacy [36]. Logan
et al. observed similar effects and also incorporated drugs sensitive to
US-induced cavitation into the MB complex [37].
Previous MB-spheroid studies have neglected to incorporate any
fluid flow conditions into their systems, a physical parameter that is
vastly important in tissues and drug delivery. The lack of fluid flow fails
to recreate the constant supply and removal of nutrients and waste
products experienced in vivo, as well as failing to subject cells to ap-
propriate shear stresses. In addition, most therapeutic agents are de-
livered by direct injection into the cardiovascular system, and interact
with tissues under flow conditions. Microfluidic technology offers a
solution to these limitations, allowing for the maintenance of spheroid
cultures under constant flow. As a result, various microfluidic spheroid
culture systems have been developed, using micro-well arrays, trapping
chambers and droplet-based microfluidics to culture and trap spheroids
[38–43]. Previous trapping chambers have employed the use of gravity
traps to capture pre-grown spheroids. This method allows for a high
trapping efficiency, but it is relatively low throughput. In addition, the
spheroids cannot be recovered from the traps, therefore analysis is
limited to imaging-based assays only. Single-cell suspensions are often
seeded into microfluidic spheroid systems to allow for on-chip forma-
tion of spheroids. Whilst this has the advantage of forming high num-
bers of spheroids under flow, the narrow cell loading channels often do
not allow for retrieval of the spheroids after treatment, again meaning
quantitative assays cannot be performed. Qualitative data obtained
from imaging of spheroids using fluorescence microscopy alone can also
be problematic to quantify, due to the scattering effects observed to-
wards the centre of large spheroids.
We present a microfluidic system that allows for high numbers of
spheroids to be exposed to therapeutic agents under physiologically
relevant flow conditions. Spheroids were trapped in microfluidic de-
vices and subjected to passive, gravity driven flow with velocities mi-
micking those found in blood capillaries (0.3–1 mm/s) [44]. The use of
integrated reservoirs over conventional syringe pumps eliminated the
issues associated with operating syringe pumps and tubing in con-
junction with an incubator. Furthermore, separate media sources al-
lowed multiple devices to be ran in parallel with different therapeutic
exposures. Each experiment allowed for up to 100 spheroids to be
trapped across 12 self-contained devices, each of which could be sub-
jected to a variety of therapeutic exposures. The trap design also al-
lowed for simple spheroid retrieval by the reversal of flow, enabling the
quantitative analysis of spheroid viability off-chip using an Adenosine
TriPhosphate (ATP) viability assay. Overall, this system provided a
platform which could supply physiological rates of fluid flow to pre-
grown HCT116 colorectal cancer (CRC) and Human Foetal Foreskin
Fibroblast (HFFF2) spheroids. Spheroid cultures could be easily
trapped, exposed to therapeutics under flow, and retrieved for quanti-
tative analysis. This system was subsequently used to investigate the
effect of MB-enhanced drug delivery on spheroid viability. The effect of
free and liposomal doxorubicin (DOX) co-delivered with US activated
MBs was investigated and compared to the effects of DOX alone. Con-
focal imaging and ATP assay results showed that MBs enhanced both
drug accumulation and efficacy in both free and liposomal treatments.
2. Materials and methods
2.1. Cell culture and spheroid production
HCT116 (ECACC 91091005) and HFFF2 (ECACC 86031405) were
both originally obtained from ECACC (UK). Cells were STR profiled to
ensure authenticity and regularly tested for mycoplasma. Cells were
grown and maintained in DMEM 10% FBS (Thermo Fisher, UK), with
1% Glutamax (Gibco, UK), in an incubator at 37 ° C, 5 % CO2. 200 μL of
a 7.5 × 102 cells/mL cell suspension in a 1:1 HCT116 - HFFF2 ratio was
seeded into ultra-low attachment 96 well-plates (Corning, Costar) and
spheroids were allowed to develop for 5 days.
2.2. Microfluidic device fabrication
Polydimethylsiloxane (PDMS) microfluidic devices were fabricated
using standard photolithography and soft lithography techniques
[45,46]. SU8-2075 photoresist was spin coated onto a 3-in. silicon
wafer then baked for 90 min. This process was repeated, giving a total
resist height of approximately 350 μm. A direct write 375 nm UV laser
(DWL, Durham Magneto Optics) selectively exposed the photoresist and
patterned the microfluidic design. The wafer was baked for a further 90
min then excess photoresist removed using Microposit EC solvent (Dow,
US). PDMS (Sylgard 184, Dowsil) was mixed in a 10:1 base:curing agent
ratio, poured onto the wafer and desiccated for 40 min to remove any
bubbles. PDMS was then cured at 80 ° C for a 1 h. Devices were then
cut, hole-punched and bonded to PDMS coated glass microscope slides
using oxygen plasma. Fabricated devices were then sterilised in an
autoclave at 120°C for 40 min. Reservoirs were fabricated from 16 mm
diameter polycarbonate (Engineering & Design Plastics) cut into 32 mm
long pieces. Reservoirs were fabricated to contain a 2 mm wide spout
protruding from the bottom of each container. This allowed for simple
interfacing with 2 mm hole-punched inlets and outlets in the micro-
fluidic. Lids were fabricated by gluing 0.22 μm PTFE filters (Cole-
Parmer) onto the top of Delrin (Par-group) rings, which then slotted
over the top of the reservoirs. 0.22 μm filters prevented bacterial con-
tamination of the media. Reservoirs were autoclaved at 120°C for
40 min and the underside of the reservoir lids sterilised under UV light
for 30 min prior to experimental use.
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2.3. Device setup and operation
As a first step, each device was flushed with ethanol to wet the
channel surfaces and ensure no air bubbles remained lodged within the
traps. The inlet and outlet of each device could be accessed directly
through the bottom of each reservoir using a 200 μL pipette. Ethanol
was removed and the device flushed through with PBS (+Ca, +Mg,
Gibco, UK) then DMEM 10% FBS (Thermo Fisher, UK), 1% Glutamax
(Gibco, UK). Spheroids were then collected from each low-adhesion
well and deposited into the inlet reservoir. Prior to loading, spheroids
were imaged and sized using SpheroidSizer [47]. Spheroids with a
diameter in the range of 280–350 μm were then identified for loading
on chip. 10 spheroids were loaded into each inlet reservoir and allowed
to flow into the device. The hydrodynamic force from media flow en-
sured that spheroids remained in their traps, unless subjected to back-
flow. Once spheroids had been trapped, media from both reservoirs was
removed and the therapeutic compound added to the inlet reservoir.
For MB exposures, MBs were directly pipetted into the channel through
the reservoir spout, preventing MBs from rising to the top of the re-
servoir by their intrinsic buoyancy. The MB sample was pipetted up to
the end of the inlet serpentine channel, meaning no MBs passed through
the chamber at high rates of flow. Excess sample was deposited into the
reservoir before media was added to induce flow at the desired flow
rates. Therapeutic exposure was stopped by simply removing all com-
pound-containing media and refilling the inlet reservoir with fresh
media.
2.4. DOX preparation and DOX-LS production
DOX (100 mg, Generon, UK) was dissolved in 5 mL DMSO then
further diluted in DMEM to the required concentration (1–10 μM).
DMSO concentration was kept below 0.5% (v/v) to limit toxicity and
prevent any reduction in cell viability. LS (55mol % DSPC, 40mol %
Cholesterol and 5mol % DSPE-PEG2000 (Lipoid, GE)) were produced
via extrusion through a 200 nm filter membrane. LS were extruded in
ammonium sulphate (300 mM), with the pH adjusted to 7.2 using so-
dium hydroxide (0.1 M). LS were then dialysed in sterile ultrapure
water overnight to remove any excess buffer. DOX hydrochloride
(4 mg/mL, Fluorochem, UK) was then loaded into the LS, using the pH
gradient from the ammonium salt to actively load the DOX.
Unencapsulated DOX was removed using a NAP-5 gel filtration column
(GE Healthcare, USA). LS concentration was determined using a
NanoSight NS300 (Malvern Panalytical) and typically found to be
2–4 × 1012 LS/mL. The amount of DOX encapsulated inside the LS was
determined by comparing absorbance at 500 nm of a known, lysed
concentration of LS with a DOX calibration curve produced using the
absorbance of known DOX concentrations. LS were lysed using 0.2%
Triton X-100 (Sigma, UK) and the absorbance measured using a
UV–Vis-NIR spectrophotometer (Cary 5000, Agilent, USA). 1 × 1010 LS
were found to contain, on average, 3.5 μg of DOX. This gave an ap-
proximate encapsulation efficiency of 79% after cleaning.
2.5. MB and DLMB production
MBs were prepared from a mixture of DPPC and DSPE-PEG2000 in a
95:5 M ratio and a total lipid concentration of 2 mg/mL. Lipids were
dissolved in a 1:1 mixture of chloroform and methanol and dried under
nitrogen to remove the solvent, then resuspended in PBS solution
containing 1% glycerol in a sonicating water bath. The lipid solution
was then combined with C4F10 gas in a microfluidic device for MB
production as described previously [48]. After production, the MB size
and concentration distribution were measured optically using bright-
field microscopy and analysed using a custom MATLAB (2017b,
MathWorks, USA) script. MBs were diluted in PBS to a final con-
centration of ~108 MB/mL with an average diameter between 1 and
2 μm (Supplementary Fig. S1). Experiments containing fluorescent MBs
used DOPE Atto488 lipids (0.2%) in MB production. DLMBs were
produced using 5% DSPE-PEG2000-Biotin (Avanti Polar Lipids, USA) in
both MB and LS preparations. Neutravidin (10 μM, Thermofisher Sci-
entific, USA) was then used to bind LS and MBs.
2.6. Ultrasound instrumentation and exposure
Microfluidic devices were insonated using a 2.25 MHz centre fre-
quency unfocused transducer (V323-SM, Olympus, US). Ultrasound
pulses were controlled by a function generator (TG5011, Agilent
Technologies, UK) and consisted of a duty cycle of 1%, pulse repetition
frequency of 1 kHz for a total duration of 2 s. The free field transducer
output was calibrated using a 0.2 mm needle hydrophone (Precision
Acoustics, UK) to provide a peak negative pressure of 0.81 ± 0.04 MPa
when driven by a + 53 dB RF power amplifier (A150, Electronics %
Innovation, US). The transducer was coupled to the top of the micro-
fluidic device via a gel pad (Aquaflex, Parker Laboratories, US) and
coupling gel. Use of a gel standoff pad meant that the spheroid chamber
was further than the Rayleigh distance away from the transducer, en-
suring that the spheroid chamber was exposed to the far field, uniform
US beam. The PDMS device was fabricated to be 1 mm thick to mini-
mise US attenuation. Peak negative pressure with 1 mm of PDMS in
front of the hydrophone was measured to be 0.81 ± 0.04 MPa, a re-
duction from 0.94 ± 0.01 MPa in degassed ultrapure water. This gave
a Mechanical Index (MI) of 0.54 ± 0.03. The pressures recorded with
the hydrophone only gave an approximation for the acoustic pressure
produced on-chip, as attenuation due to PDMS alone is an over-
simplifcaiton. Local pressure variations will arise due to acoustic re-
flections from the glass coverslip and device geometry. Nevertheless,
complete acoustic characterisation of the system was not necessary, as
total destruction of the MBs was the only requirement for this in-
vestigation.
2.7. ATP viability assay
CellTiter-Glo 3D cell viability assay (Promega, USA) was used as an
endpoint assay to determine spheroid viability. Spheroids were re-
trieved from the chip 48 h after exposure by withdrawing via a pipette
inserted into the inlet reservoir. The lack of adhesion between cells and
PDMS means spheroids can be easily dislodged by backflow. Spheroids
were allowed to grow a further 48 h after exposure to allow for mea-
surement of the chemotherapeutic effect on cell division. Untreated
control spheroids were grown for the same length of time and used in
comparison. Spheroids from each chip were deposited in a volume of
100 μL into each well of an opaque-walled 96 well-plate. 100 μL of
assay reagent was mixed into each well and incubated at room tem-
perature for 30 min. Luminescence was then recorded on a plate reader
(SpectraMax M2E, Molecular Devices, USA) as per assay instructions.
To account for variation in initial spheroid diameter, and by extension
volume, final luminescence values were normalised with respect to a
300 μm diameter spheroid. Normalisation factors were determined for
each chip using the average volume of the 10 spheroids loaded.
2.8. Confocal imaging
A Leica DMi8/SP8 confocal microscope system was used for fluor-
escent imaging of spheroids. DOX and NucRed Dead dye (Thermo
Fisher Scientific, USA) were excited sequentially using 488 nm OPSL
and 638 nm Diode lasers respectively. Fluorescence emission for DOX
was measured from 410 to 493 nm and for NucRed Dead emission
between 651 and 799 nm. Images were acquired approximately 100 μm
from the top of the chamber, allowing the upper sections of the
spheroid to be viewed. A 10× objective was used with the confocal
pinhole set to 2 A.U., giving an approximate axial image thickness of
19 μm.
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3. Results and discussion
3.1. Device design and optimisation
In order to capture as many spheroids as possible and improve assay
statistics, careful consideration of the design of the microfluidic device
was required. Fig. 1a shows a single spheroid trap with dimensions
(orange D1, D2 and D3) and fluidic resistances associated with flow
through and around the obstacle (green R1 and blue R2 lines). The
spheroid traps were designed by considering the ratio of hydraulic re-
sistances through, R1, and around, R2, each trap. These hydraulic re-
sistances are dependent on trap dimensions such as trap diameter, D1
(300–350 μm), centre channel width, D2 (120–250 μm), trap length, D3
(400–600 μm), and distance between traps (400 μm). These calcula-
tions were originally considered by Xu et al. (2013), who used this
technique to optimise the trapping of 5 μm microspheres in trap arrays
[49]. The same framework was applied to this scaled-up system to
optimise trap geometry for the trapping of 320 μm spheroids. The
overall trap array design was based on single-cell culture arrays ori-
ginally designed by Di Carlo et al. [50]. The main development from
this initial design is the inclusion of a central trap channel, the primary
function of which is to control resistances through the array.
Resistances through and around each trap were calculated to be on
the order of 10−9 Pa. s/m3. Traps with resistance ratios (R1/R2) from 1
to 5 were designed and modelled in Ansys Fluent (Supplementary Fig.
S2) to observe the change in flow behaviour through each trap. Traps
were then fabricated and tested to determine the trapping efficiency,
defined as the total number of spheroids trapped out of the 10 loaded
onto each chip. A resistance ratio of 2.1 was determined to be optimal
for this system, resulting in a trapping efficiency, on average, of 70 %
for 320 μm spheroids. Traps with a lower ratio, such as 1.3, were cre-
ated by widening the centre channel to 250 μm. This however, resulted
in spheroids deforming through the centre of the traps when under high
flow rates (≥0.8 μL/s). Higher ratios of ≥3.1 reduced the flow through
each trap in turn, reducing the probability of a spheroid becoming
trapped. The ratio chosen balanced each of these effects to optimise
trapping efficiency. In addition to the resistance ratio, trapping effi-
ciency was also found to be dependent on spheroid diameter. Fig. 1b
shows a plot of trapping efficiency (%) against average spheroid dia-
meter (μm) for traps with a resistance ratio of 2.1, recorded over several
experiments. As the spheroid size increased from 220 μm to 350 μm in
diameter, the trapping efficiency also increased from ~ 10% to 75%.
Again, high flow rates (≥0.8 μL/s) used in spheroid loading caused
smaller spheroids (< 280 μm) to overshoot the traps or deform through
the centre channel, decreasing the trapping efficiency. A mean occu-
pancy of 6 ± 2 spheroids per chip was achieved across all experiments
(minimum of 1, maximum of 11). Together, this consistent trapping
efficiency and chip parallelisation allowed for high throughput
spheroid testing compared to pre-existing microfluidic spheroid sys-
tems.
Fig. 2a shows a schematic of the microfluidic trap system, showing
the centre array containing 17 individual traps used to capture the
spheroids and long serpentine channels to increase device hydraulic
resistance and regulate flow rate. Fig. 2b shows a brightfield micro-
scopy image of spheroids trapped inside the chamber of the device. As
an alternative to using conventional syringe pumps, fluid was driven
passively through the device using integrated reservoirs and hydrostatic
pressure. This allowed for multiple systems to be run in parallel without
the need for large numbers of syringe pumps, enabling the high
throughput testing of multiple therapeutics. Reservoirs were slotted
into the inlet and outlet of each device, then the inlet reservoir filled
with media to initiate flow (Supplementary Fig. S3). The height dif-
ference in fluid levels in inlet and outlet reservoirs results in a hydro-
static pressure imbalance, inducing fluid flow until levels have equili-
brated. Flow rates through the device were then dependent on the
difference between inlet and outlet reservoir fluid levels, as well as the
channel geometry.
Serpentine channels, each 13 mm long, were used to increase the
hydraulic resistance of the device and reduce the flow rate to produce
capillary-like flow in the spheroid chamber. Fig. 2c shows a plot of
theoretical flow rate and measured flow rate, determined by tracking
the trajectory of 2 μm fluorescent beads. Beads were recorded flowing
through the chamber and their linear velocities were determined using
MosaicSuite ImageJ particle tracking plugin (http://mosaic.mpi-
cbg.de/?q=downloads/imageJ). Linear velocities were found to vary
between 0.2 and 0.85 mm/s through the chamber for reservoir height
differences of 5–20 mm, corresponding to volumetric flow rates of
0.19–0.78 μL/s. From these observations, the hydraulic resistance
throughout the entire system was determined to be (2.5 ± 0.1) × 1011
Pa. s/m3. This was lower than the theoretical resistance of 3.6 × 1011
Pa. s/m3 calculated using the Poiseuille flow solution for rectangular
shaped channels [51]. This disagreement can, in part, be attributed to
an assumption made in the Poiseuille flow model when calculating the
hydraulic resistance of the channel. This assumes a very flat, wide
channel (h/w → 0) which was not the case for the serpentine channels
in this device (h/w ≈ 1) [51]. Nevertheless, flow rates achieved
through the use of reservoirs successfully emulated flow velocities
found within capillaries (0.3–1 mm/s). The resulting shear stress in-
duced from these flow rates was estimated by modelling flow passing
Fig. 1. a) Diagram showing spheroid trap dimensions and the hydraulic re-
sistance for fluid flowing through, R1 or around, R2 the trap. b) Plot of observed
trapping efficiency against average spheroid diameter. Average of 56 spheroids
per point.
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over spheroids occupying the traps (Supplementary Fig. 4). It was found
that the average shear stress experienced by each spheroid was 11± 2
dynes/cm2, well within the physiological range of 1–70 dynes/cm2
[52].
3.2. Spheroid response to free doxorubicin
To demonstrate the suitability of the microfluidic device for high-
throughput screening, a proof-of-principle exposure of trapped spher-
oids to free DOX was performed. This experiment also allowed for the
50% inhibitory concentration (IC50) to be determined for spheroids on-
chip. Off-chip exposure of DOX to monoculture and co-culture spher-
oids revealed that DOX concentrations between 0 and 10 μM resulted in
a typical dose response curve (Supplementary Fig. S5). IC50 values were
determined to be 0.9 ± 0.1 μM and 1.9 ± 0.2 μM for monoculture
and co-culture spheroids, respectively. This range was therefore used to
determine the on-chip dose-response. The exposure of spheroids to free
DOX and the corresponding change in cell viability would also act as a
comparison for future MB experiments. Spheroids were cultured off-
chip, and subsequently loaded and trapped across 38 chips (n = 185
spheroids). Trapped spheroids were exposed to DOX for 8 h. DOX was
then removed from the device, then fresh media added and replaced
every 24 h. 48 h after exposure, NucRed Dead cell stain was added to
the inlet reservoir then washed away after 30 min. Spheroids were
imaged using confocal fluorescence microscopy to observe DOX accu-
mulation and cell death. Fig. 3a shows spheroids trapped on-chip 48 h
after being exposed to different concentrations of DOX (0 (control), 1, 5
and 7.5 μM). The left column shows the brightfield images of spheroids,
with the middle column showing the corresponding fluorescence
emission from DOX and the right column the emission from the dead
stain.
Spheroids exposed to 1 μM DOX showed no observable reduction in
spheroid integrity, with relatively low levels of DOX observed
throughout the spheroid and few dead cells around the spheroid per-
iphery. A 5 μM DOX exposure resulted in significant spheroid de-
gradation. The outer layers of the spheroid appear to break down and
emission from the dead stain confirms mass cell death in these layers.
High levels of DOX emission were observed in the spheroid core, which
still appeared intact and alive. Exposure to 7.5 μM DOX caused further
degradation of the outer layers. The mass cell death resulted in the loss
of spheroid integrity, which gave rise to the outer layers of the spheroid
being washed away under flow as the spheroid was unable to maintain
its structure. The spheroid core remaining in the trap also showed dead
cell fluorescence, suggesting the spheroid was minimally viable. Cells
broken away from degraded spheroids could be observed to collect in
the base of the outlet reservoir. The backflow used to collect spheroids
also collected these fragments, so that analysis using ATP included all
cells cultured in the device, alive and dead.
Spheroids were retrieved off chip by first adding media to the outlet
reservoir to reverse the flow direction. A pipette was then attached to
the inlet and very carefully withdrawn, pulling the spheroids from their
traps. This could be achieved with low flow velocities due to the
minimal adhesion of spheroids to PDMS. Spheroids were then analysed
using CellTiter-Glo 3D cell viability assay. This assay, specifically de-
signed for 3D spheroid cultures, lyses all of the cells, releasing ATP – a
direct indicator of cellular viability. The ATP is then converted to a
luciferase product which is detected as luminescence using a plate
reader. The luminescence of the DOX-treated spheroids was then ex-
pressed as a percentage with respect to control spheroids that had
simply been allowed to grow untreated for 48 h. Fig. 3b shows per-
centage spheroid viability for each DOX exposure with a dose response
curve fitted to determine the IC50 value. ATP assay results showed that
1 μM DOX had minimal effects on spheroid viability 91 ± 8 %, 5 μM
DOX had a greater effect on viability 45 ± 9 %, whilst 7.5 μM DOX
reduced spheroid viability substantially 27 ± 9 % . A higher dose of 10
μM DOX had only a slight increased effect on spheroid viability 20 ± 2
% compared to 7.5 μM. The remaining cells were likely to be quiescent
cells which show resistance to many therapies due to minimal uptake of
drugs as a result of low metabolic activity [53]. The dose-response
curve revealed an IC50 value of 4 ± 0.1 μM. The IC50 indicated that a
concentration of 3 μM would be ideal for free DOX and MB co-delivery
experiments. This dosage resulted in a small reduction in spheroid
viability 75 ± 4 % when administered as free drug alone, allowing for
further reductions in viability to be demonstrated by the same DOX
concentration, but including MBs. Overall, the agreement between
imaging observations and ATP assay results gave confidence in the
system's ability to produce reliable, consistent results.
Fig. 2. a) Spheroid trap design showing serpentine channels and a central trapping chamber. b) Multiple HCT116 – HFFF2 spheroids trapped within the trap array. c)
Plot of theoretical and measured flow rates against the difference in the inlet and outlet reservoir fluid heights.
M.D. Bourn, et al. Journal of Controlled Release 326 (2020) 13–24
17
Fig. 3. (a) Bright field, doxorubicin (DOX) and dead cell (NucRed Dead) fluorescent emission from spheroids 48 h post exposure to 0 (control), 1, 5 and 7.5 μM DOX.
(b) Spheroid viability with increasing concentrations of DOX, measured 48 h post exposure with CellTiter-Glo 3D cell viability assay (n = 146).
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18
3.3. Ultrasound and microbubble spheroid exposure
To determine the effect of co-delivering DOX with MBs, it was first
necessary to observe the effect of the US trigger (+ US) alone, MBs
(without US) and MBs + US exposures on spheroid viability. Fig. 4a
shows the experimental setup used to expose the spheroid chamber to
US. MB destruction in the device was tested under stopped flow con-
ditions. Observation of MB concentrations across the chamber before
and after US insonation found that 99.96 % of MBs were destroyed by
the US pulse (Supplementary Fig. S6).
Spheroids were loaded into the chamber and exposed to the US
trigger only (n = 24), MB only (n = 12) and MB + US (n = 26). 30 μL
of MBs (108 bubbles/mL) were loaded on chip then media was added to
initiate flow. Supplementary Video 1 shows MBs in the trap array,
flowing over and around the spheroids. MB + US chips were then ex-
posed to the US trigger in order to destroy the MBs. In order to better
observe the interaction between MBs (+US) and tumour spheroids,
fluorescent Atto488 (0.2 mol%) lipids were incorporated into the lipid
shell of the MBs during production. Observation of lipid deposition and
associated cell death would indicate that effective MB-induced sono-
poration was occurring. An increase in lipid transfer from MBs after
destruction would also suggest that this effect would facilitate uptake of
DOX-LS conjugated to MBs. Spheroids exposed to MB only and
MB + US were imaged 8 h after exposure, with NucRed dead stain
again being used to observe any cell death.
Fig. 4b shows images taken of control, MB only and MB + US
spheroids trapped on-chip, 8 h after exposure. Brightfield images (left
column) show no observable spheroid degradation in any of the ex-
perimental conditions. Lipid deposition (central column, Atto 488
fluorescence) shows negligible signal in control spheroids, as expected.
Spheroids exposed to MB only showed small amounts of fluorescent
lipid scattered across the surface whereas, spheroids exposed to
MB + US showed increased amounts of fluorescent lipid deposition.
Together these images indicate that fluorescent lipids from MBs are
passively exchanged with spheroids as MBs flow across the surface. In
contrast, destruction of MBs using US results in greater amounts of lipid
exchange as lipids are sonoprinted onto the spheroid surface.
Comparison of dead cell detection (right column, NucRed fluorescence)
showed minimal cell death occurred in MB alone treatment. Whereas,
when the MBs had been destroyed, multiple dead cells were visible on
the surface of the spheroid which were directly associated with fluor-
escent lipid locations. The correlation of lipids and cell death indicated
that MB destruction with US resulted in irreversible sonoporation, in
which cell death occurs as a result of pore formation in cell membranes.
Fig. 4c shows the ATP assay results for each of the experimental
conditions. Comparison of spheroid viabilities from US only
(101 ± 6%), MB only (94 ± 5%) and MB + US (97 ± 9%) ex-
posures showed no statistically significant difference compared to
control values when subjected to a Mann-Whitney (MW) non-para-
metric U test. To better evaluate the data obtained in each exposure, a
95% confidence interval test was performed on each data set. This value
describes the range around the mean in which there is a 95% certainty
it contains the true mean. This was determined to be±3.2%,±
4.5%,±2.7% and ± 6.6% for control, US only, MB only and
MB + US exposures. The overlap of confidence intervals with the
control interval gave further evidence that these exposures were not
having a significant effect on spheroid viability. Overall, the spheroid
viability results confirmed that these control exposures to MB and
MB + US had no adverse effects on the spheroid's structural integrity or
viability. Lower viabilities were observed across two sets of spheroids
exposed to MB + US. This could be attributed to the cell death cause by
MB destruction which is indicative of irreversible sonoporation where
pores fail to reseal after insonation [54]. Hu et al. observed this effect
alongside many other partial membrane perforations that eventually
resealed [55]. That study used a 1:1 MB to cell ratio, here the ratio of
nearby MBs to outer layer spheroid cells only is estimated to be ap-
proximately 1.5:1, suggesting similar numbers MB sonoporation events
will be occurring. However this estimate cannot account for the effects
of flow on local MB concentrations or any potential MB accumulation.
The NucRed dead cell stain used throughout this series of experiments
is comparable to propidium iodide (PI) which is often used to study the
production of pores from MB sonoporation. Both compounds only be-
come fluorescent when entering a perforated cell membrane, allowing
for the observation of compromised cell membranes. Considerable
Fig. 4. a) Diagram of ultrasound setup with microfluidic chip and transducer. b) Bright field, Atto 488 lipid and dead cell (NucRed Dead) fluorescent emission from
spheroids 8 h post exposure to MBs with and without US. c) A boxplot of spheroid viability with US, MB and MB + US exposures. Each data point represents a single
chip. Box plots show range (whiskers), interquartile range (outer box), 95% confidence interval (hashed box) and mean (line). Annotated values show (mean ± S.E).
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numbers of dead cells could be observed in spheroids exposed to
MB + US, however this appeared to have minimal effect on the overall
spheroid viability measured 48 h later.
3.4. Co-delivery of free DOX with MBs + US
Next, the effectiveness of US triggered MBs as drug delivery en-
hancers was investigated by co-delivering 3 μM DOX with MBs to
spheroids. The experiment was performed using the same setup and
Fig. 5. (a) Bright field, DOX and dead cell (NucRed Dead) fluorescent emission from spheroids 48 h post exposure to 3 μM DOX only, with US and with MB + US. (b)
Spheroid viability for spheroids 48 h post exposure to 3 μM DOX free drug alone (n = 39), with US (n = 26) and with MB + US (n = 31). Each data point represents
a single chip.
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time points as in previous sections, to allow for direct comparison be-
tween results. Along with the complete therapeutic combination of
DOX + MB + US, a control DOX + US (without MBs) was included for
comparison. Fig. 5a shows brightfield, DOX emission and NucRed
emission cell images taken of spheroids 48 h post-exposure to each of
the conditions. A trend in decreasing spheroid structural integrity and
core density with DOX only, DOX + US then DOX + MB + US can be
observed in brightfield images. Similar observations were made with
increasing free drug concentrations and is indicative of increased drug
penetration and decreased spheroid integrity. Decreased core density
was also accompanied by evidence of cells shedding from the outer
layers of the spheroid, an effect which only occurred in spheroids
subjected to higher concentrations of DOX in previous experiments.
Fluorescent DOX imaging shows a clear increase in fluorescence in-
tensity from DOX only treatment to the complete exposure condition.
This suggests that DOX + US and DOX +MB+ US exposures allow for
increased DOX accumulation into spheroids. Fluorescence from dead
cells was only observed around the periphery of spheroids exposed to
DOX only. However, dead cells were found much further into the centre
of the spheroid when DOX was delivered alongside MB + US, sug-
gesting the destruction of the MBs in close proximity increased drug
penetration into the spheroids.
Spheroids were once again retrieved using backflow and the ATP
assay used to quantify spheroid viability. Fig. 5b shows the boxplot of
spheroid viability for each therapeutic exposure. Results show that the
combination of 3 μM DOX + US (without MB) reduced spheroid via-
bility to 61 ± 1 %, and 3 μM DOX + US + MB reduced viability to
48 ± 2 %. These values were both significantly lower than that of free
3μM DOX 75 ± 4 % . The p values in each case were found to
be< 0.0001 (****), illustrating the highly significant statistical differ-
ence between the groups.
The free DOX dose response curve indicates that a DOX con-
centration of approximately 4.8 μM would be required to reduce
spheroid viability to 45%. This indicated an increase in DOX efficacy at
the lower concentration of 3 μM of approximately 60% when co-de-
livered with MB+ US. Spheroids exposed to free 5 μM showed a similar
viability 45 ± 9 % to the 3 μM DOX + MB + US along with com-
parable amounts of drug accumulation and cell death (Fig. 3(a) and
5(a)), suggesting that the presence of MBs and US allowed for lower
doses of DOX to be delivered for an equivalent therapeutic effect. It is
evident that the sonoporation caused by MB destruction increased drug
penetration and accumulation and overall effectiveness of the DOX.
These observations are in agreement with previous studies into the
effects of sonoporation on the delivery of drugs to tumours [56,57].
Escoffre et al. show that co-delivery of DOX and MBs enhanced both
early and late stage DOX-induced cell apoptosis, leading to a similar
increase in DOX efficacy as observed in this study [58]. However, this
study was conducted on static glioblastoma and breast cell monolayers
and relied on live/dead cell counting assays for viability results. Thus
limiting the validity of a comparison between our studies. It was also
observed in these experiments that DOX efficacy was improved with the
use of US alone, giving an average spheroid viability of 61 ± 1 %. In
the previous control, US alone was observed to have no significant ef-
fect on spheroid viability, indicating that there may be an interaction
between DOX and US that increases drug efficacy. One explanation for
this effect is US-induced acoustic streaming exerting shear stress on cell
membranes and increasing permeability [59,60]. Similar synergistic
effects of DOX + US co-delivery have previously been observed and
become more significant with longer and more intense US exposures
[57,61–63].
3.5. Co-delivery of drug loaded MBs with US trigger
The previous results showed the efficacy of free DOX + MB + US
when administered to CRC spheroids. However, in a clinical setting, the
use of free DOX presents many limitations due to its cardio myopathic
side effects. Encapsulation of DOX inside LS provided a solution to this
issue - with liposomal DOX being observed to have an improved toxicity
profile and reduced cardiac effects compared to its free counterpart.
Conjugation of DOX LS to MBs offers a method by which DOX can be
delivered locally to tumours. Insonation of these drug-loaded MBs
(DLMBs) at the tumour site would allow for release and uptake of DOX-
LS exclusively in surrounding tumour tissues. The following experi-
ments investigated the effects of DOX-LS only, DOX-LS co-delivered
with MBs and US (DOX-LS +MB+US) and finally, DOX-LS conjugated
to the lipid shell of the MBs, delivered with US (DLMBs + US). This
allowed for the effects of DOX-LS, with no MBs, unconjugated MBs and
conjugated MBs on spheroids to be observed. In addition to this, the
effect of multiple US exposures with DLMBs was investigated. The vo-
lume of the spheroid chamber is ~6 μL, meaning the entire 30 μL DLMB
solution could fill the chamber 5 times. Separate DLMB-spheroid chips
were therefore exposed to 1, 3 and 5 US exposures with 60s given be-
tween each exposure to allow the chamber to refill with DLMBs. This
was to define whether multiple DLMB destructions increased drug de-
livery to spheroids.
DLMBs were produced as described in the methods. In order to in-
vestigate the effect of DOX-LS and DLMBs compared to free DOX of
previous experiments, the concentration of DOX-LS was adjusted to
deliver an equivalent DOX concentration of 3 μM. DLMBs were pro-
duced so that the same number of MBs and total DOX dose was con-
tained within the 30 μL solution administered to each chip. This was
followed by the same volume of medium used in free DOX experiments
to keep the total volume consistent. The same exposure regime and
analysis was performed as in previous sections.
Fig. 6a shows bright field, DOX emission and NucRed dead stain
fluorescence emission from spheroids exposed to DOX-LS, DOX-
LS + MB + US and DLMB + US (x3). Comparison of DOX accumu-
lation in spheroids exposed to DOX-LS and DOX-LS + MB + US shows
little difference in drug penetration or DOX accumulation. A similar
number of dead cells were also observed across each set of spheroids.
This suggests that the co-delivery of DOX-LS + MB + US does not
facilitate the delivery of DOX-LS into tumour spheroids. The pores
created in the cell membrane from MB sonoporation must not allow for
substantial transfer of DOX-LS into the cell. Spheroids exposed to DLMB
+ US (x3) showed increased DOX accumulation and dead cell detection
in the outer layers of the spheroids when compared conditions in which
DOX-LS were not attached to the MB surface. However, there was no
observable trend in the amount of DOX accumulated or number of dead
cells with the number of DLMB + US exposures (Supplementary Fig.
S7). This indicated that the maximum therapeutic effect is achieved
after only one US exposure.
Fig. 6b shows the boxplot of spheroid viability after DOX-LS, DOX-
LS + MB + US and DLMB US (x1, 3 and 5) exposures. Analysis of
spheroids after DOX-LS and DOX-LS +MB+ US exposures found mean
viability values of 74 ± 3 % and 76 ± 3 % respectively. No statistical
significance was found between the datasets, further substantiating that
increased DOX-LS accumulation does not occur when DOX-LS are co-
delivered rather than conjugated to MBs. Spheroid viability showed no
difference with repeated DLMB + US exposures - 59 ± 5 %, 61 ± 6
% and 65 ± 4 % for DLMB US x1, x3, and x5 respectively. This was in
agreement with imaging observations which also showed no substantial
differences in cell death or drug accumulation. Comparison between
spheroid viabilities from DOX-LS and DLMB exposures found statisti-
cally significant differences with every number of US exposures, again
agreeing with imaging observations.
Exposure of spheroids to DOX-LS, with and without unconjugated
MBs, was found to have an equivalent effect on spheroid viability when
compared to an equal dose of free DOX. This largely disagrees with
previous studies which often show free DOX having a greater effect over
DOX-LS. The apparent increase in liposomal DOX efficacy observed in
this study could be attributed to increased mass transport of DOX-LS
into the outer layers of spheroids. Increased mass transport due to the
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shear stress induced from fluid flow would demonstrate that the pre-
sence of fluid flow is a very important parameter in drug studies.
Research from Kang et al. found that the uptake of polystyrene nano-
spheres was increased on average 50% for a range of tumour cell lines,
due to biomimetic rates of shear stress [64,65]. Shear stress has also
been found to increase the effectiveness of liposomal DOX compared to
static delivery, however this study again demonstrated that free DOX
reduced cell viability more than of liposomal DOX [66]. Another po-
tential reason for the increase in DOX-LS efficacy is the method by
which the drug is delivered on-chip. A total dose of DOX-LS equivalent
to the 2 mL, 3 μM free DOX dose was initially loaded on-chip in a 30 μL
volume, then followed by 2 mL of media. The initial local DOX-LS
Fig. 6. (a) Bright field, DOX and dead cell (NucRed Dead) fluorescent emission from spheroids 48 h post-exposure to Free LS, LS + MB (free) and DLMB US x3. (b)
Spheroid viability for spheroids 48 h post exposure to Free LS (n = 38), LS + MB (free) (n = 66), DLMB x1 (n = 73), x3 (n = 70) and x5 (n = 71). Each data point
represents a single chip.
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concentration will therefore be considerably higher and may have al-
lowed for increased instantaneous accumulation, further facilitated by
the inertial cavitation of MBs.
DOX-LS did not show any increased efficacy when delivered
alongside free MBs + US (Fig. 6b). Similar amounts of fluorescent DOX
emission from each set of spheroids suggests that the sonoporation in-
duced by MB bursting does not facilitate the effective delivery of un-
conjugated DOX-LS to the outer layers of the spheroid. In contrast to the
co-delivery of DOX-LS and MBs, DLMBs were found to be more effective
in decreasing spheroids viability. Similar results were observed by
Roovers et al. which, also found a lack of increased DOX-LS efficacy
when no conjugated to MBs + US [36]. Assay results show that, on
average, DLMB's reduced spheroid viability to 62 ± 3 %, a decrease of
approximately 15% from DOX-LS and DOX-LS + MB + US exposures.
Spheroid viability across each DLMB exposure was found to vary con-
siderably suggesting that there is either varying amounts of DOX-LS
being delivered to the spheroids or, varying amounts of release occur-
ring from the DOX-LS. Allowing a longer period of time between drug
exposure and analysis of viability may reduce the spread in data as
more complete DOX release from DOX-LS occurs. However, this would
only be the case if similar numbers of DOX-LS were being delivered to
each spheroid. This could also allow for the effects of MB-enhanced
drug delivery to be better observed, as the effects of increased LS ac-
cumulation become more significant with time. Interestingly, the
number of US exposures did not appear to have an effect on the amount
of DOX delivered to spheroids. It is suggested that the outer layers of
cells in the spheroid become saturated with DOX-LS after the first US
exposure, rendering any further exposures ineffective as more DOX-LS
are delivered to cells already containing cytotoxic numbers of DOX-LS.
Perhaps a more effective treatment regime could use repeat exposures
with longer time intervals. This could allow time for the initial DOX-LS
exposure to take effect and cause outer layer cell death. Subsequent
exposures would then target the remaining healthy cells revealed as
outer layer cells die.
Confocal imaging of DOX accumulation throughout spheroids ex-
posed to DLMB shows DOX-LS were mainly found localised to the outer
cell layers. What was most interesting about this observation, is the fact
that the cells in which DOX was observed are not present in the
spheroid at the time of treatment. These outer layer cells imaged 48 h
after treatment were observed to grow within the first 24 h and were
not present in the outer layers of the spheroid at the time of treatment.
It is suggested that the initial slow release kinetics of DOX from the
liposomes allows for cells to continue to divide even after the initial
DLMB treatment, due to the early-stage non-toxic concentrations of
DOX. As more DOX is released from LS, concentrations become sig-
nificant enough to cause cytotoxic effects and decrease spheroid via-
bility. The release of DOX from Doxil and similar DOX-LS under phy-
siological conditions has previously been reported to be very slow,
showing only 5% release over 24 h [67]. Seynhaeve et al. studied the
intracellular release of DOX from Doxil LS, comparing results with free
DOX treatments [68]. Measuring the amount of DOX within cells 24 h
after treatment found significantly lower amounts from cells exposed to
Doxil, indicating minimal DOX release across this time. Similar ob-
servations were also made by Roovers et al. in a recent MB spheroid
paper, in which DOX-LS were found to release little DOX 72 h after MB
destruction [36].
Contrary to these observations, spheroids exposed to DOX-LS
throughout this study were growth inhibited by a substantial amount in
any exposure. These viabilities, along with imaging observations, sug-
gest that significant amounts of DOX was being released from LS
throughout the 48 h period. A potential mechanism for this release
could be presence of ammonia at the tumour spheroid site. Ammonia is
produced by tumour cells by glutaminolysis, the metabolic process
which tumour cells often favour over the normal glycolytic pathway in
order to meet cell energy requirements [69]. A recent study in-
vestigated drug release from Doxil with ammonia, finding that drug
release is increased up to 80% across 48 h in the presence 50 mM
ammonium sulphate [70]. This process of release is similar to that of
the DOX-LS loading process, where the uncharged DOX diffuses across
the liposome membrane and then becomes deprotonated, preventing it
from passing back through the bilayer [71]. A further driver of this
glutaminolysis release mechanism may be the hypoxic conditions cre-
ated at the centre of tumour spheroids. The enzyme responsible for the
production of glutamate and ammonia from glutamine, glutaminase 1
(GSL1) has been observed to be stimulated by the production of hypoxic
inducible factor 1 (HIF1) in colorectal cancers. HIF1 is a potent inducer
of cancer cell proliferation, invasion and metastasis, all of which were
found to be dependent on the upregulation of GSL1 and subsequent
glutaminolysis [69]. The lack of hypoxic conditions in the relatively
small, 100 μm spheroids used throughout Roovers et al. (2019) MB
study compared to the hypoxic conditions created at the centre of
≥300 μm spheroids throughout this study, may be a factor affecting the
lack of drug release observed in their study. However, direct observa-
tion of GSL1/HIF1 involvement in DOX-LS release would be required to
confirm this connection.
4. Conclusions
This study presented a new microfluidic device allowing for the
trapping, culture and MB-therapeutic testing of tumour spheroid co-
cultures under physiological flow conditions. The self-contained system
design allowed for simple multiplexing, enabling the high throughput
screening of multiple therapeutic conditions in parallel. The micro-
fluidic trap design allowed for straightforward spheroid retrieval and
subsequent quantitative analysis of spheroid viability. This was sup-
plemented with confocal imaging, which enabled spheroid degradation,
drug accumulation and cell death to be observed. The use of micro-
fluidics to create in vivo-like rates of flow and shear stress further en-
hanced the physiological relevance of the 3D culture system. Indeed,
several results observed throughout this paper could be attributed to
the effects of flow-induced shear stress, and may provide further insight
into the mechanism of these therapeutics in vivo.
Overall, the co-delivery of MBs + US with DOX has been shown to
increase drug efficacy in both free and liposomal formulations. DLMBs
have been shown offer a promising method of delivering drugs to tu-
mours, offering both increased efficacy and localised delivery in com-
parison to DOX-LS alone. It is evident that bursting of DLMB facilitates
the uptake of DOX-LS into the tumour tissue, however this process does
not appear result in the release of DOX from DOX-LS. This is advanta-
geous in minimising the systemic dose of DOX whilst also ensuring
maximum localised DOX-LS delivery. The lack of associated vasculature
within the spheroids limits the ability of this study to predict the extent
of this effect in vivo, and the recently developed vasculature on-chip
models may present a system where this could be further investigated
[72–74]. It known that the endothelium will present an additional
barrier that must be overcome to effectively deliver drugs to the tu-
mour. However, endothelial cells have been shown to be equally as
susceptible to the effects of MB induced sonoporation, suggesting that a
similar increase in drug efficacy may be observed as in this study
[75,76].
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jconrel.2020.06.011.
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